Department of Health and Human Services Food and Drug Administration 21 Cfr Part 101 Food Labeling: Health Claims and Label Statements; Folic Acid and Neural Tube Defects
نویسنده
چکیده
Agency: Food and Drug Administration, HHS. Action: Final Rule. __________________________ SUMMARY: The Food and Drug Administration (FDA) is announcing its decision not to authorize a health claim for folic acid and neural tube defects at this time. However, consistent with the recently announced recommendations of the U.S. Public Health Service (PHS) that all women of childbearing age in the United States consume 0.4 milligram (mg) (400 micrograms (pg)) of folic acid daily to reduce their risk of having a pregnancy affected with spina bifida or other neural tube defects. FDA plans to work expeditiously to authorize a claim, if appropriate. At that time the PHS identified several issues that remain outstanding, including the appropriate level of folic acid in food and safety concerns regarding increased intakes of folic acid. Given the significance of neural tube defects and the PHS recommendation, the agency is continuing to address the issues about folic acid. FDA recently convened an advisory committee to consider the outstanding concerns (57 FR 52781, November 5,1992). The advisory committee provided recommendations to the agency on the following issues: (1) What is the target population for a folic acid neural tube defect health claim? (2) How does the information available on the effective level of intake affect options for implementation? (3) What safety concerns for the target population and for persons in the general population must be addressed? and (4) If a claim is authorized, what is the most appropriate method for presenting it to the target population? The advisory committee’s recommendations are currently under FDA review.
منابع مشابه
Letter Regarding Dietary Supplement Health Claim for Omega-3 Fatty Acids and Coronary Heart Disease
This letter is in reference to the court decision directing the Food and Drug Administration (FDA) to reconsider the health claim “Consumption of omega-3 fatty acids may reduce the risk of coronary heart disease” in dietary supplement labeling (Pearson v. Shalufu, 164 F.3d 650 (D.C. Cir. 1999)). FDA has sent you replies on two of the other health claims that the court directed FDA to reconsider...
متن کاملOf Health and Human Services 21 Cfr
SUMMARY: The Food and Drug Administration (FDA) is adopting general requirements pertaining to: (1) The use of health claims that characterize the relationship of a substance to a disease or health related condition on the labels and in labeling of foods in conventional food form (conventional foods), and (2) the content of petitions regarding the use of such health, claims pertaining to specif...
متن کاملI-8: Folic Acid and Female Fertility in Natural and Assisted Reproduction
Background Pre-conceptional supplementation with folic acid is recognized as essential for the prevention of neural tube defects. However, the reproductive effects of folic acid may extend well beyond this well-recognized effect and may have an important role in improving fertility and survival of the conceptus and fetus. MaterialsAndMethods We evaluated the association between pre-conceptional...
متن کاملDEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 172 [Docket No. 91F-0228] Food Additives Permitted For Direct Addition to Food For Human Consumption; Sucrose Acetate Isobutyrate
The Food and Drug Administration (FDA) is amending the food additive regulations to provide for the safe use of sucrose acetate isobutyrate (SAIB) as a stabilizer of emulsions of flavoring oils used in nonalcoholic beverages. This action is in response to a petition filed by Eastman Chemical Co. DATES: Effective (inserl date of publication in the Federal Register); written objections and reques...
متن کاملFolic Acid and Vitamin B12 Fortifi cation of Flour: A Global Basic Food Security Requirement
Folic acid is an essential water soluble B vitamin which has been used for decades in the prevention of folate defi ciency anemia of pregnancy. In 1991, folic acid taken prior to the start of pregnancy was shown unequivocally to prevent spina bifi da and anencephaly—two of the most serious and common birth (neural tube) defects. Soon governments recommended that women of reproductive age consum...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2004